
CANF Stock Forecast & Price Target
CANF Analyst Ratings
Bulls say
Can-Fite Biofarma Ltd is positioned favorably in the biopharmaceutical market, driven by its robust pipeline, particularly the drugs Piclidenoson and Namodenoson. The company is projected to achieve significant revenue growth, with risk-adjusted global sales estimated to rise from approximately $3 million in 2027 to $126 million by 2031, indicating strong market potential. The advancement of Namodenoson into Phase III trials for hepatocellular carcinoma and positive outcomes from ongoing studies further enhance the outlook for Can-Fite, highlighting the potential for breakthrough therapies in competitive indications.
Bears say
Can Fite Biofarma Ltd faces significant challenges that negatively impact its financial outlook, primarily due to the risk of unsuccessful commercialization of its products, which could hinder expected revenue growth. The company has reported a net loss of $4.9 million for the first half of 2025, with projections indicating a deeper annual loss of $10 million, raising concerns about financial sustainability. Additionally, potential delays in regulatory approvals, patient enrollment in clinical trials, and competitive pressures may further restrict the company's ability to capitalize on its therapeutic candidates and generate revenues.
This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.
CANF Analyst Forecast & Price Prediction
Start investing in CANF
Order type
Buy in
Order amount
Est. shares
0 shares